R.

657 posts

R.

R.

@sertidman

Katılım Nisan 2023
11 Takip Edilen54 Takipçiler
Prof. Dr. Güner Sönmez
Prof. Dr. Güner Sönmez@DrGunerSonmez·
Şimdiye kadarki en güçlü zayıflama ilacı Retatrutide, obezite tedavisinde çığır açacak gibi: Hastalar 80 haftada ortalama ağırlıklarının %28’ini kaybetti. Ağır obez grupta oran %30’u geçti. Bu, obezite ameliyatlarına yaklaşan ve mevcut ilaçların hiçbirinin ulaşamadığı bir etki.
Türkçe
54
169
2K
255.6K
ATİLLA KORTEL
ATİLLA KORTEL@hasankurtul·
@DrGunerSonmez Yan etkileri zararları nelerdir karaciğere böbreklere pankreasa zararı var mı zayıflarken organlarımızı elimize vermesinler..
Türkçe
1
0
0
1.1K
R. retweetledi
Bryan Johnson
Bryan Johnson@bryan_johnson·
These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for retatrutide: > highest dose lost 28.3% of body weight in 80 wks > 70 lbs ave > 45% lost 30% or more of their body weight > 65% on the top dose no longer clinically obese Retatrutide is more dynamic than semaglutide and tirzepatide because it targets three receptors (GIP, GLP-1, and glucagon), versus one and two, respectively. Side effects, on the highest dose (12mg), were higher for retatrutide than tirzepatide (nausea and GI), with an 11.3% drop out rate. The lowest 4mg dose still delivered 19% loss with fewer dropouts than placebo.
Bryan Johnson tweet media
English
237
224
3.9K
1.5M
R.
R.@sertidman·
Elon musk bile övüyor, cidden bu reta mucize
Max Marchione@maxmarchione

Retatrutide phase 3 obesity trial just came out and the results are genuinely insane: - 28.3% bodyweight lost on 12mg over 80 weeks - 70.3 pounds on avg. or 31.9 kg - 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory) - 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients - 65.3% of 12mg patients dropped below the obesity BMI threshold - 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%) - significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP - no cardiac or liver signals Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time.

Türkçe
0
0
0
110
R. retweetledi
Max Marchione
Max Marchione@maxmarchione·
Retatrutide phase 3 obesity trial just came out and the results are genuinely insane: - 28.3% bodyweight lost on 12mg over 80 weeks - 70.3 pounds on avg. or 31.9 kg - 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory) - 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients - 65.3% of 12mg patients dropped below the obesity BMI threshold - 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%) - significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP - no cardiac or liver signals Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time.
Max Marchione tweet media
English
313
718
7.2K
2.5M
önce vatan
önce vatan@vatan2506·
@sertidman @DrGunerSonmez Yan etkisi oldumu?Bu ilaç reçete ediliyor mu?Edilmiyorsa fiyatı ne kadar?Lütfen cevap verirseniz sevinirim.
Türkçe
1
0
0
505
Merve
Merve@Merve13473274·
@DrGunerSonmez Çok iyi Türkiye de yoktur gelse bile çok pahalı olur 😌her şey bize zor çok
Türkçe
1
0
1
3.8K

Keşfet

@maxmarchione @MatthewParrott @uzuncimen @DrGunerSonmez @Alparsl41755100 @esin89077140 @hasankurtul @gracecilikkkkk